BIO-CAT provides the very latest enzyme technology and custom formulations. Founded in 1988, our extensive range of products, from single-to-multi-enzyme blends, service various industrial, food, agriculture and other commercial markets. BIO-CAT is an FSSC 22000 certified facility in Virginia featuring state-of-the-art laboratories for scientific research, product development and on-site quality testing to better serve customers.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDTECH

WITH "PRODRUGS FOR CANCER TREATMENT" PATENT, GATC HEALTH ENTERS ONCOLOGY MEDICINE MARKET

GATC Health Corp | April 22, 2022

news image

GATC Health, a biotech company that uses artificial intelligence and advanced multiomics to revolutionize drug discovery and disease prediction, announced that it filed a patent application for an innovative new prodrug designed to safely cross the blood-brain barrier (BBB) for cancer treatment. GATC Health's entry into the oncology drug discovery market is marked by this breakthrough, which was made possible by the company's innovative Multiomics Advanced TechnologyTM AI platform....

Read More

INDUSTRIAL IMPACT

ETHERNA ANNOUNCES RESEARCH AGREEMENT WITH MERCK KGAA, DARMSTADT, GERMANY TO ACCESS MRNA TECHNOLOGIES

eTheRNA | February 04, 2022

news image

eTheRNA immunotherapies NV ("eTheRNA") is pleased to announce the start of a strategic partnership with Merck KGaA, Darmstadt, Germany with the signing of a Research Agreement. The partnership will investigate the application of eTheRNA's proprietary mRNA design expertise and LNP-delivery platforms to disease areas selected by Merck KGaA, Darmstadt, Germany. The ongoing pandemic has underlined the capability for mRNA vaccines as a new therapeutic modality. eTheRNA an...

Read More

CELL AND GENE THERAPY

SPECIFIC BIOLOGICS INC. ANNOUNCES THERAPEUTIC DEVELOPMENT AWARD FROM THE CYSTIC FIBROSIS FOUNDATION

Specific Biologics Inc. | December 08, 2021

news image

Specific Biologics Inc. an early-stage biotechnology company developing novel gene editing technologies, announced that it will receive more than US$527,000 to support the preclinical development of its Dualase™ gene editing platform to target a set of cystic fibrosis -causing nonsense mutations where patients currently have fewer therapeutic options available. "Incredible advancements in the treatment of cystic fibrosis have been made since the id...

Read More

INDUSTRIAL IMPACT

PICTOR ANNOUNCES FUNDING ROUND AFTER SUCCESSFUL LAUNCH IN NEW ZEALAND AND USA OF SARS-COV-2 ANTIBODY TEST

Pictor | December 05, 2022

news image

Pictor, a global leader in immunodiagnostics announced a funding round to help accelerate pipeline product development projects along with market development activities within Australia/New Zealand, the US and Europe for its Human Health and Animal Health portfolios. This follows the recent successful launch of the PictArray™ SARS-CoV-2 IgG Antibody Test through Rako Science in New Zealand and key partners in the US. “The test better informs patients and doctors in det...

Read More
news image

MEDTECH

WITH "PRODRUGS FOR CANCER TREATMENT" PATENT, GATC HEALTH ENTERS ONCOLOGY MEDICINE MARKET

GATC Health Corp | April 22, 2022

GATC Health, a biotech company that uses artificial intelligence and advanced multiomics to revolutionize drug discovery and disease prediction, announced that it filed a patent application for an innovative new prodrug designed to safely cross the blood-brain barrier (BBB) for cancer treatment. GATC Health's entry into the oncology drug discovery market is marked by this breakthrough, which was made possible by the company's innovative Multiomics Advanced TechnologyTM AI platform....

Read More
news image

INDUSTRIAL IMPACT

ETHERNA ANNOUNCES RESEARCH AGREEMENT WITH MERCK KGAA, DARMSTADT, GERMANY TO ACCESS MRNA TECHNOLOGIES

eTheRNA | February 04, 2022

eTheRNA immunotherapies NV ("eTheRNA") is pleased to announce the start of a strategic partnership with Merck KGaA, Darmstadt, Germany with the signing of a Research Agreement. The partnership will investigate the application of eTheRNA's proprietary mRNA design expertise and LNP-delivery platforms to disease areas selected by Merck KGaA, Darmstadt, Germany. The ongoing pandemic has underlined the capability for mRNA vaccines as a new therapeutic modality. eTheRNA an...

Read More
news image

CELL AND GENE THERAPY

SPECIFIC BIOLOGICS INC. ANNOUNCES THERAPEUTIC DEVELOPMENT AWARD FROM THE CYSTIC FIBROSIS FOUNDATION

Specific Biologics Inc. | December 08, 2021

Specific Biologics Inc. an early-stage biotechnology company developing novel gene editing technologies, announced that it will receive more than US$527,000 to support the preclinical development of its Dualase™ gene editing platform to target a set of cystic fibrosis -causing nonsense mutations where patients currently have fewer therapeutic options available. "Incredible advancements in the treatment of cystic fibrosis have been made since the id...

Read More
news image

INDUSTRIAL IMPACT

PICTOR ANNOUNCES FUNDING ROUND AFTER SUCCESSFUL LAUNCH IN NEW ZEALAND AND USA OF SARS-COV-2 ANTIBODY TEST

Pictor | December 05, 2022

Pictor, a global leader in immunodiagnostics announced a funding round to help accelerate pipeline product development projects along with market development activities within Australia/New Zealand, the US and Europe for its Human Health and Animal Health portfolios. This follows the recent successful launch of the PictArray™ SARS-CoV-2 IgG Antibody Test through Rako Science in New Zealand and key partners in the US. “The test better informs patients and doctors in det...

Read More